Aging is a clinical syndrome.
has the solution.
The architecture of regeneration.
Moleculeon Science is a vertically integrated biotechnology group. One quality system runs from cell line to finished product, across development, manufacturing, clinical application and supply.
The platform rests on two Nobel sciences. Growth factors carry the biological instruction. Extracellular vesicles carry that instruction into the cell. Holding both lets one manufacturing base serve every division.
Vision and mission.
Setting the global benchmark for clinical-grade regenerative products, by translating breakthrough biological discoveries into scalable, high-efficacy therapeutics.
API sovereignty
Full control of the technology, from stem cell engineering through to proprietary production platforms, and the team to do it again.
The dual-Nobel engine
Stabilized growth factors and high-purity extracellular vesicles, co-formulated as one system rather than supplied side by side.
Strategic integration
Research, quality-validated manufacturing and clinical application held inside one group.
The fastest-aging societies on earth.
Taiwan passed the United Nations threshold for an aged society in 2018 and the super-aged threshold in 2025. Germany took thirty-six years to make the same crossing.
At that speed aging stops being a natural inevitability and becomes a clinical problem, arriving faster than any health system can build the capacity to answer it.
7 years
Taiwan's crossing from aged to super-aged
Japan took eleven years, Italy nineteen, Germany thirty-six. One person in five in Taiwan is now 65 or older, 20.06 percent at the end of 2025.
Problem
Aging frailty is a multi-system decline: sarcopenia, chronic inflammation and reduced physiological reserve. It drives hospitalization, disability and mortality.
Unmet need
Management is limited to nutrition and exercise. There are no approved pharmacological agents that halt the biological drivers of frailty.
Goal
A science-based, regulatory-approved therapeutic, taken through its first market and then made available globally.
Past the stem cell bottleneck.
The stem cell problem. Transplanted stem cells do not survive much beyond three weeks after injection, and their rate of actual tissue differentiation is close to zero. Autologous therapy is highly variable, impossible to standardize at commercial scale, and prohibitively expensive.
The vesicle answer. The scientific consensus now holds that stem cells heal by secreting regenerative signals rather than by becoming new tissue. We isolate the signal and discard the cell. A single master cell bank from one qualified donor, grown in controlled bioreactors, yields a standardized, off-the-shelf biologic that carries no risk of uncontrolled proliferation.
Comparison describes autologous stem cell therapy as a class against standardized extracellular vesicle manufacture. Figures describe the production model, not any specific product.
The timing is now.
Demand built over a decade, supply newly restricted by regulation, and a manufacturing base that already runs.
Edge
Built on infrastructure and science that already exist, rather than on a plan to acquire them.
Assets
ISO 22716 GMP facilities, research capability, and multiple technology positions held in our own name.
Network
A global network across industry, academia and clinical medicine.
Register interest.
One address. We will write when there is something worth saying.